New funding to take Vital's liver failure cell therapy through Phase III
This article was originally published in Scrip
Executive Summary
Vital Therapies closed the first $16 million from a $76 million funding commitment from its existing private investors to finance three pivotal Phase III clinical trials for the company's human allogeneic cellular therapy developed to treat acute liver failure.